Erlotinib plus gemcitabine in patients with unresectable pancreatic carcinoma: Results from a phase IB trial.

被引：0
|
作者：
Porterfield, BW [1 ]
Dragovich, T [1 ]
Patnaik, A [1 ]
Rowinsky, E [1 ]
Huberman, M [1 ]
Clinebell, T [1 ]
Hamilton, M [1 ]
Zitelli, A [1 ]
Nadler, P [1 ]
Wood, D [1 ]
机构：
[1] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4110
引用
收藏
页码：340S / 340S
页数：1
相关论文
共 50 条
  • [1] Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
    Tomislav Dragovich
    Mark Huberman
    Daniel D. Von Hoff
    Eric K. Rowinsky
    Paul Nadler
    Debra Wood
    Marta Hamilton
    George Hage
    Julie Wolf
    Amita Patnaik
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 295 - 303
  • [2] Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
    Dragovich, Tomislav
    Huberman, Mark
    Von Hov, Daniel D.
    Rowinsky, Eric K.
    Nadler, Paul
    Wood, Debra
    Hamilton, Marta
    Hage, George
    Wolf, Julie
    Patnaik, Amita
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (02) : 295 - 303
  • [3] Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Okusaka, Takuji
    Furuse, Junji
    Funakoshi, Akihiro
    Ioka, Tatsuya
    Yamao, Kenji
    Ohkawa, Shinichi
    Boku, Narikazu
    Komatsu, Yoshito
    Nakamori, Shoji
    Iguchi, Haruo
    Ito, Tetsuhide
    Nakagawa, Kazuhiko
    Nakachi, Kohei
    CANCER SCIENCE, 2011, 102 (02) : 425 - 431
  • [4] A phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Nakachi, K.
    Okusaka, T. O.
    Funakoshi, A. F.
    Ioka, T. I.
    Yamao, K. Y.
    Ohkawa, S. O.
    Boku, N. B.
    Komatsu, Y. K.
    Nakamori, S. N.
    Furuse, J. F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 387 - 387
  • [5] A Phase II Trial of Erlotinib in Combination With Gemcitabine and Cisplatin for Unresectable Pancreatic Cancer
    Hwang, I. G.
    Jang, J. S.
    Kang, J. H.
    Lee, G. W.
    Go, S. I.
    Kang, M. H.
    Oh, S. Y.
    Lee, S.
    Kwon, H. C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S461 - S461
  • [6] A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
    Oettle, H
    Richards, D
    Ramanathan, RK
    van Laethem, JL
    Peeters, M
    Fuchs, M
    Zimmermann, A
    John, W
    Von Hoff, D
    Arning, M
    Kindler, HL
    ANNALS OF ONCOLOGY, 2005, 16 (10) : 1639 - 1645
  • [7] A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer.
    Kortmansky, JS
    O'Reilly, EM
    Minsky, BD
    Puleio, SA
    Winkelmann, J
    Kelsen, DP
    Schwartz, GK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
  • [8] Erlotinib plus Gemcitabine in metastatic pancreatic cancer: Results from a non-interventional trial
    Westphalen, C. Benedikt
    Heinemann, Volker
    Tessen, Hans Werner
    Groschek, Matthias
    Hoeffkes, Heinz-Gert
    Marschner, Norbert
    Schulze, Mathias
    Beringer, Andreas
    Waldschmidt, Dirk
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (04): : 332 - 340
  • [9] Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.
    Qu, Yuan-Yuan
    Zou, Qing
    Guo, Hongqian
    Xing, Nianzeng
    Sun, Zhongquan
    Han, Weiqing
    Luo, Hong
    Xia, Shujie
    Zhang, Xuepei
    He, Chaohong
    Zhang, Hailiang
    Cai, Jinling
    Zhang, Xiao
    Wang, Quanren
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] A randomized phase II study comparing gemcitabine plus nadroparine versus gemcitabine in patients with locally advanced or metastatic pancreatic carcinoma: The GEMFRAX trial.
    Voorthuizen, T. V.
    Vervenne, W. L.
    Van Daalen, E. H.
    Phoa, S. S.
    Gouma, D. J.
    Bruno, M. J.
    Richel, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 205S - 205S
12345